We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App

Clinical Chemistry Instruments and Reagents Under Scrutiny at the 2015 AACC Annual Meeting

By LabMedica International staff writers
Posted on 27 Jul 2015
Print article
Image: The Altair 240 clinical chemistry analyzer (Photo courtesy of EKF Diagnostics).
Image: The Altair 240 clinical chemistry analyzer (Photo courtesy of EKF Diagnostics).
Image: The Stanbio Chemistry GSP LiquiColor Assay analyzer (Photo courtesy of EKF Diagnostics).
Image: The Stanbio Chemistry GSP LiquiColor Assay analyzer (Photo courtesy of EKF Diagnostics).
Clinical chemistry, both instrumentation and reagents, was the focus of presentations at booth 1018 at the 2015 AACC Annual Meeting & Clinical Lab Expo (Atlanta, GA, USA).

EKF Diagnostics (Cardiff, United Kingdom), a global in vitro diagnostics company, took advantage of the AACC Annual Meeting to launch the Altair 240 clinical chemistry analyzer.

This new bench-top platform represents EKF Diagnostics’ first fully integrated chemistry system designed for the global market. EKF believes that the new Altair 240 clinical chemistry analyzer fulfills an international market need for a fully automated bench-top platform supported by the reliable Stanbio Chemistry (Boerne, TX, USA) reagent menu.

“We listened to the needs of our customers and designed the Altair 240 to be easy to learn, operate, and maintain,” said Albert Blanco, business unit director at EKF Diagnostics. “Because it runs on Windows 7, operators can easily navigate its intuitive, touch screen menu. Features such as the capability to use bar coded, primary sample tubes, auto-rerun, auto-dilution and STAT interruption—all function to maximize the system’s overall efficiency.”

EKF will also use the AACC Annual Meeting venue to discuss the latest additions to its Stanbio clinical chemistry range. This range includes a large selection of clinical chemistry assays, controls, and calibrators, which are fully compatible with most major brand open channel chemistry analyzers.

A notable addition to the reagent menu is the Stanbio Chemistry Glycated Serum Protein (GSP) LiquiColor test; a new diabetes biomarker test that provides a two to three week indicator of average blood glucose. The GSP LiquiColor test is based on a double enzymatic degradation method that utilizes the specificity of fructosyl-amino oxidase to eliminate inaccuracies caused by non-glycated protein reducing substances, which significantly interfere with the NBT fructosamine method. The test is available as a liquid-stable kit with calibrator. It is suitable for use on a variety of clinical chemistry analyzers, with on-board stability of up to four weeks.

Other instruments to be highlighted at the AACC Annual Meeting include the DiaSpect and HemoPoint H2. DiaSpect is a hand held device touted as being the world’s fastest hemoglobin measurement system. The instrument is described as offering laboratory quality performance for anemia screening in all climatic conditions in less than two seconds. The HemoPoint H2 stores over 4000 patient results and is designed for use in blood banks, clinics, and hospitals. This instrument provides immediate and simultaneous high quality results for both hemoglobin and hematocrit.

Related Links:

2015 AACC Annual Meeting & Clinical Lab Expo
EKF Diagnostics
Stanbio Chemistry

Gold Supplier
Real-Time PCR System
Applied Biosystems QuantStudio 7 Pro Dx
HPLC System
Jasper HPLC System
RT-PCR Enzymes and Kits
QuantiNova Pathogen +IC Kit
Zika Virus IgM µ-Capture ELISA

Print article
IIR Middle East


Molecular Diagnostics

view channel
Image: Special blood test could determine if patient has early stage breast cancer and if the cancer is unlikely to return (Photo courtesy of USC)

Simple Blood Draw Could Revolutionize Early Breast Cancer Detection

Breast cancer is the most prevalent form of cancer in the world, affecting one in eight women over their lifetime. Since 1976 when the American Cancer Society endorsed mammography X-rays, the technique... Read more


view channel
Image: The global infectious disease IVD market is expected to hit USD 57 billion by 2030 (Photo courtesy of Pexels)

Global Infectious Disease IVD Market Dominated by Molecular Diagnostics Technology

The global infectious disease in vitro diagnostics (IVD) market stood at USD 113.7 billion in 2021 and is expected to grow at a CAGR of -7.41% from 2022 to 2030 to hit around USD 56.89 billion by 2030,... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.